Immutep LtdASX: IMM

Immutep Quarterly Activities Report and Appendix 4C

Jul 29, 2026 at 6:24 PM EDT · Issued by Immutep Ltd via ASX

Filed with ASX · Jul 29, 2026 at 6:24 PM EDT

On 6ix: 6ix.com/news/immutep-quarterly-activities-report-and-appendix-4c-3

Immutep Limited , Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889 ASX / Media Release Immutep Quarterly Activities Report & Appendix 4C Q4 FY26 • Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of...

View Attachment

6ix hasn’t read this filing yet.

Immutep Ltd on 6ix

Story so far

Immutep Quarterly Activities Report Q2 FY26Jan 29, 2026
Immutep Quarterly Activities Report Q1 FY26Oct 29, 2025
Appendix 4E & 2025 Full Year Statutory AccountsAug 29, 2025

Earlier from Immutep

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Jul 23
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway InhibitorJul 14
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004Jul 12
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patientsMay 27
Immutep Receives Nasdaq Notice of Bid Price DeficiencyApr 30

Later from Immutep

Immutep Quarterly Activities Report Q4 FY26Jul 30
Immutep Corporate PresentationAug 19
Appendix 4E & 2026 Full Year Statutory AccountsAug 30
S&P DJI Announces September 2026 Quarterly RebalanceSep 4
Immutep Outlines Focused Development Strategy for EftiSep 10

All Immutep news releases

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep